{"article": [{"url": "https://www.marketwatch.com/story/moderna-ceo-tells-ft-that-coronavirus-vaccine-wont-be-ready-by-election-day-11601516187", "published": 1601539460.0, "headline": "Moderna CEO tells FT that coronavirus vaccine won\u00e2\u0080\u0099t be ready by Election Day", "body": "In this file photo taken on Aug. 13, Moderna protocol files for COVID-19 vaccinations are kept at the Research Centers of America in Hollywood, Florida. AFP/Getty Images Moderna Inc.\u00e2\u0080\u0099s potential coronavirus vaccine will not be ready by the U.S. presidential election, the biotech company\u00e2\u0080\u0099s chief executive told the Financial Times on Wednesday. CEO St\u00c3\u00a9phane Bancel told the FT in an interview that Moderna MRNA, +0.09% \u00e2\u0080\u0094 a front-runner in the COVID-19 vaccine race \u00e2\u0080\u0094 will not seek emergency-use authorization from the U.S. Food and Drug Administration until Nov. 25 at the earliest and does not expect to have secured approval for distribution of the vaccine to the general public until spring 2021. \u00e2\u0080\u009cI think a late [first quarter], early [second quarter] approval is a reasonable timeline, based on what we know from our vaccine,\u00e2\u0080\u009d Bancel told the FT. President Donald Trump has pressed for a vaccine by Election Day, worrying some experts who fear a rushed and inadequate testing process. Don\u00e2\u0080\u0099t miss: Ex-FDA commissioners slam political interference at FDA and CDC as U.S. death toll tops 206,000 FDA Commissioner Stephen Hahn has promised that the approval process will be based on science, not politics. \u00e2\u0080\u009cFDA will not permit any pressure from anyone to change that,\u00e2\u0080\u009d Hahn said recently. \u00e2\u0080\u009cI will put the interest of the American people above anything else.\u00e2\u0080\u009d Despite Trump\u00e2\u0080\u0099s assertions that a vaccine could be ready in weeks, Centers for Disease Control and Prevention Director Robert Redfield told Congress earlier this month that widespread vaccinations are not expected until well into next year. Cambridge, Mass.\u00e2\u0080\u0093based Moderna has one of seven coronavius vaccine candidates being tested in the U.S., and one of four to have advanced to late-stage trials. MarketWatch video: This is how much it costs to develop a vaccine In August, Moderna said the U.S. government had agreed to buy 100 million doses of its vaccine candidate, with an option to buy 400 million more doses, for $2.48 billion in total. Moderna shares are up more than 261% in 2020, compared with the benchmark S&P 500\u00e2\u0080\u0099s SPX, +0.87% 4% year-to-date gain. Moderna shares were lower by 1% in premarket trades on Thursday. Read on: FDA broadens U.S. safety inquiry into AstraZeneca COVID-19 vaccine, report says"}]}